DDInter119 DDInter262
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
Cabozantinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Cabozantinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Epoprostenol
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Cabozantinib may lead to a major life threatening interaction when taken with Epoprostenol
Cabozantinib may lead to a major life threatening interaction when taken with Troleandomycin
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Cabozantinib may lead to a major life threatening interaction when taken with Flurbiprofen